Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial
2020; Elsevier BV; Volume: 21; Issue: 3 Linguagem: Inglês
10.1016/s1470-2045(19)30817-4
ISSN1474-5488
AutoresRobert H. Jones, Angela Casbard, Margherita Carucci, Catrin Cox, Rachel Butler, Fouad Alchami, Tracie‐Ann Madden, C. Bale, Pavel Bezecny, Johnathan Joffe, Sarah Moon, Chris Twelves, Ramachandran Venkitaraman, Simon Waters, Andrew Foxley, Sacha J. Howell,
Tópico(s)PI3K/AKT/mTOR signaling in cancer
ResumoCapivasertib (AZD5363) is a potent selective oral inhibitor of all three isoforms of the serine/threonine kinase AKT. The FAKTION trial investigated whether the addition of capivasertib to fulvestrant improved progression-free survival in patients with aromatase inhibitor-resistant advanced breast cancer.
Referência(s)